Drug
Alxn2050
Alxn2050: highest development phase Phase 1, developed by Alexion. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alexion
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALXN2050 NCT04933682 | Phase 1 | |
| ALXN2050 NCT05047458 | Phase 1 | Healthy |
Latest
No recent events.
Follow Alxn2050 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.